Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Nat Med. 2024 Aug;30(8):2373. doi: 10.1038/s41591-024-03161-w.

Nabil F Saba^{1

2}, Conor E Steuer^{3

4}, Asari Ekpenyong⁴, Ashley McCook-Veal^{4

5}, Kelly Magliocca^{4

6}, Mihir Patel^{4

7}, Nicole C Schmitt^{4

7}, William Stokes^{4

8}, James E Bates^{4

8}, Soumon Rudra^{4

8}, Jill Remick^{4

8}, Mark McDonald^{4

8}, Marin Abousaud⁹, Aik Choon Tan¹⁰, Muhammad Zaki Hidayatullah Fadlullah¹⁰, Ritu Chaudhary¹¹, Jameel Muzaffar¹¹, Kedar Kirtane¹¹, Yuan Liu^{4

5}, Georgia Z Chen³, Dong M Shin^{3

4}, Yong Teng^{3

4}, Christine H Chung¹¹

¹ Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA. [email protected].
² Winship Cancer Institute of Emory University, Atlanta, GA, USA. [email protected].
³ Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
⁴ Winship Cancer Institute of Emory University, Atlanta, GA, USA.
⁵ Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, USA.
⁶ Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
⁷ Department of Otolaryngology, Emory University, Atlanta, GA, USA.
⁸ Department of Radiation Oncology, Emory University, Atlanta, GA, USA.
⁹ Astellas Pharma Global Development Inc., Astellas Pharma, Northbrook, USA.
¹⁰ Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
¹¹ Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL, USA.

No abstract available

Publication types